Related Experiment Video

Updated: May 2, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

1.1K

The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells

Frederik Köpper1, Anna Maria Binkowski1, Cathrin Bierwirth1

  • 1Institute of Molecular Oncology; Göttingen Centre of Molecular Biosciences (GZMB); Faculty of Medicine; University of Göttingen; Göttingen, Germany.

Cell Cycle (Georgetown, Tex.)
|February 22, 2014
PubMed

Insights

MAPK-activated protein kinase 2 (MK2) mediates gemcitabine efficacy in pancreatic cancer cells. Inhibiting MK2 enhances survival in gemcitabine-sensitive cells but not resistant ones, highlighting MK2 as a key factor in pancreatic cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Pancreatic carcinoma is a major cancer where gemcitabine is a first-line therapy.
  • Cellular resistance to gemcitabine remains a significant challenge in treating pancreatic cancer.
  • Identifying factors that determine gemcitabine sensitivity is crucial for improving treatment outcomes.

Purpose of the Study:

  • To investigate the role of MAPK-activated protein kinase 2 (MK2) in determining gemcitabine sensitivity in pancreatic cancer cells.
  • To explore whether MK2 inhibition affects gemcitabine-induced DNA damage and cell death in pancreatic cancer.

Main Methods:

  • Utilized pancreatic cancer cell lines with varying gemcitabine sensitivities (BxPC-3, MIA PaCa-2, Panc-1, PaTu 8902).
  • Administered gemcitabine and inhibited MK2 using specific inhibitors.
  • Assessed DNA damage response intensity (e.g., H2AX phosphorylation) and cell survival rates.
  • Investigated the interaction between MK2 inhibition and checkpoint kinase 1 (Chk1) inhibition.

Main Results:

  • MK2 inhibition reduced DNA damage response and enhanced survival in gemcitabine-sensitive pancreatic cancer cell lines (BxPC-3, MIA PaCa-2, Panc-1).
  • MK2 inhibition had minimal impact on DNA damage response and survival in the gemcitabine-resistant cell line (PaTu 8902).
  • In sensitive cells, MK2 inhibition rescued increased H2AX phosphorylation caused by combined gemcitabine and Chk1 inhibition.

Conclusions:

  • MK2 plays a critical role in mediating gemcitabine efficacy in responsive pancreatic cancer cells.
  • The p38/MK2 pathway is a determinant of gemcitabine's effectiveness against pancreatic cancer.
  • Targeting MK2 could be a potential strategy to overcome gemcitabine resistance or enhance its efficacy in pancreatic cancer.
Keywords:
Chk1DNA damageMAPKAPK2MK2chemotherapygemcitabinepancreatic carcinoma

More Related Videos

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment09:56

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

Published on: April 30, 2019

7.9K
Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence08:07

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

2.4K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K